Publication
Epigenetic disruption of miR-130a promotes prostate cancer by targeting SEC23B and DEPDC1
dc.contributor.author | Ramalho-Carvalho, João | |
dc.contributor.author | Martins, João Barbosa | |
dc.contributor.author | Cekaite, Lina | |
dc.contributor.author | Sveen, Anita | |
dc.contributor.author | Torres-Ferreira, Jorge | |
dc.contributor.author | Pinho dos Santos Graça, Maria Inês | |
dc.contributor.author | Costa-Pinheiro, Pedro | |
dc.contributor.author | Eilertsen, Ina Andrassy | |
dc.contributor.author | Antunes, Luís | |
dc.contributor.author | Oliveira, Jorge | |
dc.contributor.author | Lothe, Ragnhild A. | |
dc.contributor.author | Henrique, Rui | |
dc.contributor.author | Jerónimo, Carmen | |
dc.date.accessioned | 2017-01-20T15:08:33Z | |
dc.date.available | 2017-01-20T15:08:33Z | |
dc.date.issued | 2017 | |
dc.description.abstract | MicroRNAs (miRNAs) are small, non-coding RNAs that mediate post-transcriptional gene silencing, fine tuning gene expression. In an initial screen, miRNAs were found to be globally down-regulated in prostate cancer (PCa) cell lines and primary tumors. Exposure of PCa cell lines to a demethylating agent, 5-Aza-CdR resulted in an increase in the expression levels of miRNAs in general. Using stringent filtering criteria miR-130a was identified as the most promising candidate and selected for validation analyses in our patient series. Down-regulation of miR-130a was associated with promoter hypermethylation. MiR-130a methylation levels discriminated PCa from non-malignant tissues (AUC=0.956), and urine samples revealed high specificity for non-invasive detection of patients with PCa (AUC=0.89). Additionally, repressive histone marks were also found in the promoter of miR-130a. Over-expression of miR-130a in PCa cells reduced cell viability and invasion capability, and increased apoptosis. Putative targets of miR-130a were assessed by microarray expression profiling and DEPD1C and SEC23B were selected for validation. Silencing of both genes resembled the effect of over-expressing miR-130a in PCa cells. Our data indicate that miR-130a is an epigenetically regulated miRNA involved in regulation of key molecular and phenotypic features of prostate carcinogenesis, acting as a tumor suppressor miRNA. | pt_PT |
dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
dc.identifier.citation | Ramalho-Carvalho, J., Martins, J. B., Cekaite, L., Sveen, A., Torres-Ferreira, J., Graça, I., Costa-Pinheiro, P., Eilertsen, I. A., Antunes, L., Oliveira, J., Lothe, R. A., Henrique, R., & Jerónimo, C. (2017). Epigenetic disruption of miR-130a promotes prostate cancer by targeting SEC23B and DEPDC1. Cancer Letters, 385, 150–159. https://doi.org/10.1016/j.canlet.2016.10.028 | |
dc.identifier.doi | 10.1016/j.canlet.2016.10.028 | pt_PT |
dc.identifier.issn | 0304-3835 | |
dc.identifier.uri | http://hdl.handle.net/10400.22/9335 | |
dc.language.iso | eng | pt_PT |
dc.peerreviewed | yes | pt_PT |
dc.publisher | Elsevier | pt_PT |
dc.relation.publisherversion | http://www.sciencedirect.com/science/article/pii/S0304383516306498 | pt_PT |
dc.subject | miR's epigenetic regulation | pt_PT |
dc.subject | miR-130a | pt_PT |
dc.subject | miRNA | pt_PT |
dc.subject | Prostate cancer | pt_PT |
dc.subject | SEC23B | pt_PT |
dc.subject | DEPDC1 | pt_PT |
dc.title | Epigenetic disruption of miR-130a promotes prostate cancer by targeting SEC23B and DEPDC1 | pt_PT |
dc.type | journal article | |
dspace.entity.type | Publication | |
oaire.citation.endPage | 159 | pt_PT |
oaire.citation.startPage | 150 | pt_PT |
oaire.citation.title | Cancer Letters | pt_PT |
oaire.citation.volume | 385 | pt_PT |
person.familyName | Pinho dos Santos Graça | |
person.givenName | Maria Inês | |
person.identifier.orcid | 0000-0003-1383-4242 | |
person.identifier.scopus-author-id | 6505981373 | |
rcaap.rights | restrictedAccess | pt_PT |
rcaap.type | article | pt_PT |
relation.isAuthorOfPublication | 8316e6ce-cc0a-41e6-90ab-910c93868670 | |
relation.isAuthorOfPublication.latestForDiscovery | 8316e6ce-cc0a-41e6-90ab-910c93868670 |